Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.

Starting from the known FXR agonist GW 4064 1a, a series of stilbene replacements were prepared. The 6-substituted 1-naphthoic acid 1b was an equipotent FXR agonist with improved developability parameters relative to 1a. Analog 1b also reduced the severity of cholestasis in the ANIT acute cholestatic rat model.

[1]  S. Kitamura,et al.  Metabolic activation of the proestrogens trans-stilbene and trans-stilbene oxide by rat liver microsomes. , 2000, Toxicology and applied pharmacology.

[2]  R. Evans,et al.  Benefit of farnesoid X receptor inhibition in obstructive cholestasis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Kliewer,et al.  Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. , 2005, Cell metabolism.

[4]  M. Makishima,et al.  Identification of a nuclear receptor for bile acids. , 1999, Science.

[5]  T. Willson,et al.  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.

[6]  J. Lehmann,et al.  Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.

[7]  D. Moore,et al.  Nuclear Receptor-Dependent Bile Acid Signaling Is Required for Normal Liver Regeneration , 2006, Science.

[8]  Yun Yen,et al.  Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. , 2007, Cancer research.

[9]  Ke Ma,et al.  Farnesoid X receptor is essential for normal glucose homeostasis. , 2006, The Journal of clinical investigation.

[10]  J. Hook,et al.  Induction of drug-metabolizing enzymes and toxicity of trans-stilbene oxide in rat liver and kidney. , 1981, Toxicology.

[11]  Masahiro Tohkin,et al.  Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.

[12]  Sander M Houten,et al.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. , 2004, The Journal of clinical investigation.

[13]  P. Edwards,et al.  FXR signaling in metabolic disease , 2008, FEBS letters.

[14]  A. Morelli,et al.  Cross-Talk between Farnesoid-X-Receptor (FXR) and Peroxisome Proliferator-Activated Receptor γ Contributes to the Antifibrotic Activity of FXR Ligands in Rodent Models of Liver Cirrhosis , 2005, Journal of Pharmacology and Experimental Therapeutics.

[15]  T. Willson,et al.  Protective Effects of 6-Ethyl Chenodeoxycholic Acid, a Farnesoid X Receptor Ligand, in Estrogen-Induced Cholestasis , 2005, Journal of Pharmacology and Experimental Therapeutics.

[16]  A. Grefhorst,et al.  Transient impairment of the adaptive response to fasting in FXR‐deficient mice , 2005, FEBS letters.

[17]  A. Morelli,et al.  The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. , 2004, Gastroenterology.

[18]  Jasmine Chen,et al.  Identification of a nuclear receptor that is activated by farnesol metabolites , 1995, Cell.

[19]  P. Edwards,et al.  FXR Deficiency Causes Reduced Atherosclerosis in Ldlr−/− Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[20]  L. Moore,et al.  Identification of a chemical tool for the orphan nuclear receptor FXR. , 2000, Journal of medicinal chemistry.

[21]  Grace Guo,et al.  The Farnesoid X-receptor Is an Essential Regulator of Cholesterol Homeostasis* , 2003, The Journal of Biological Chemistry.

[22]  Timothy M Willson,et al.  Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Bookout,et al.  Prevention of cholesterol gallstone disease by FXR agonists in a mouse model , 2004, Nature Medicine.

[24]  J. Ward,et al.  Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. , 2007, Carcinogenesis.

[25]  S. Fiorucci,et al.  Role of FXR in regulating bile acid homeostasis and relevance for human diseases. , 2005, Current drug targets. Immune, endocrine and metabolic disorders.

[26]  M. Bowman,et al.  A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. , 2003, Molecular cell.

[27]  A. Morelli,et al.  A Farnesoid X Receptor-Small Heterodimer Partner Regulatory Cascade Modulates Tissue Metalloproteinase Inhibitor-1 and Matrix Metalloprotease Expression in Hepatic Stellate Cells and Promotes Resolution of Liver Fibrosis , 2005, Journal of Pharmacology and Experimental Therapeutics.

[28]  S. Kliewer,et al.  FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption Published, JLR Papers in Press, September 6, 2007. , 2007, Journal of Lipid Research.

[29]  S. Asano,et al.  Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray. , 2008, Acta histochemica.

[30]  Bryan Goodwin,et al.  Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. , 2003, The Journal of clinical investigation.

[31]  S. Kliewer,et al.  Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. J. Sinal,et al.  Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice Published, JLR Papers in Press, September 26, 2005. DOI 10.1194/jlr.M500390-JLR200 , 2005, Journal of Lipid Research.

[33]  Roberto Pellicciari,et al.  Structural basis for bile acid binding and activation of the nuclear receptor FXR. , 2003, Molecular cell.